文献速递泌尿男性生殖肿瘤

安罗替尼治疗晚期肾细胞癌的长期随访结果

[Long term follow-up results of anlotinib in the treatment of advanced renal cell carcinoma].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2020-01-01

该研究基于两项Ⅱ期临床试验的单中心数据,回顾性分析36例晚期肾细胞癌患者接受安罗替尼治疗的疗效与安全性。中位无进展生存12.6个月,疾病控制率97.2%,3-4级不良反应以高血压最常见。

要点

  • 安罗替尼在晚期肾细胞癌中显示良好抗肿瘤活性,中位PFS 12.6个月。
  • 疾病控制率达97.2%,部分缓解率30.6%。
  • 3-4级不良反应主要为高血压(19.4%)和手足皮肤反应(11.1%)。

核心结论

  • 安罗替尼在晚期肾细胞癌治疗中表现出良好的抗肿瘤活性且总体耐受性良好。

研究设计与样本

  • 单中心回顾性分析,数据来自两项Ⅱ期临床研究,共纳入36例晚期肾细胞癌患者。

主要发现

  • 11例(30.6%)获部分缓解,24例(66.7%)疾病稳定,疾病控制率97.2%。
  • 中位无进展生存12.6个月,1年生存率80.6%,中位生存时间22.2个月。
  • 至随访截止,3例患者无进展生存时间分别为52.6、65.0和66.7个月。
  • 3-4级治疗相关不良反应:高血压19.4%、手足皮肤反应11.1%、蛋白尿5.6%、贫血5.6%。

临床怎么用

  • 安罗替尼可作为晚期肾细胞癌的治疗选择之一,需关注高血压和手足皮肤反应等不良反应。

局限性

  • 单中心回顾性数据,样本量较小(36例),来自两项Ⅱ期研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: Anlotinib is an oral multi-target tyrosine kinase inhibitor (TKI) with dual effects of anti-proliferation and anti-angiogenesis. Phase Ⅰ clinical trials showed anlotinib was well tolerated and had therapeutic effects on a variety of tumors. The aim of this study is to explore the safety and efficacy of anlotinib in the treatment of metastatic renal cell carcinoma. Methods: Between January 2014 and November 2015, a single-center data was obtained from a phase Ⅱ clinical study of anlotinib versus sunitinib on advanced renal cell carcinoma and a phase Ⅱ clinical study of anlotinib on advanced renal cell carcinoma which failed to respond to TKI treatment. Kaplan-Meier method was used for survival analysis, while Log-rank test was used to compare the survival rates. Results: A total of 36 patients with advanced renal cell carcinoma were enrolled in this study, including 19 patients without any target drug treatment, 12 patients with sunitinib treatment and 5 patients with sorafenib treatment. The median number of treatment cycle was 16. Partial response (PR) was obtained in 11 patients (30.6%) and stable disease (SD) was obtained in 24 patients (66.7%). The disease control rate (DCR) was 97.2%. The median progression free survival (PFS) was 12.6 months, the 1-year survival rate was 80.6%, and the median survival time was 22.2 months. Up to the follow-up deadline, 3 patients still received treatment, the PFSs were 52.6 months, 65.0 months, and 66.7 months. The most common treatment-related adverse events of grade 3 or 4 included hypertension (19.4%), hand-foot skin reaction (11.1%), proteinuria (5.6%) and anemia (5.6%). Conclusions: Anlotinib shows good anti-tumor activity and is generally well-tolerated in the treatment of advanced renal cell carcinoma. The adverse reactions of anlotinib are milder than sunitinib or pazopanib. 目的: 探索安罗替尼治疗转移性肾细胞癌的安全性和有效性。 方法: 收集2014年1月至2015年11月安罗替尼对比舒尼替尼治疗晚期肾细胞癌的Ⅱ期临床研究和安罗替尼治疗酪氨酸激酶抑制剂治疗失败的晚期肾细胞癌的Ⅱ期临床研究的单中心数据,评价安罗替尼治疗晚期肾细胞癌的疗效和安全性。生存分析应用Kaplan-Meier法,生存率的比较采用Log rank检验。 结果: 共纳入36例晚期肾细胞癌患者,其中19例患者未接受过靶向药物治疗,12例患者接受过舒尼替尼治疗,5例患者接受过索拉非尼治疗。全组患者中位治疗16个周期。11例(30.6%)患者获得部分缓解,24例(66.7%)患者获得疾病稳定,疾病控制率达97.2%。中位无进展生存时间为12.6个月,1年生存率为80.6%,中位生存时间为22.2个月。至2020年1月,3例患者未进展,无进展生存时间分别为52.6、65.0和66.7个月。安罗替尼治疗的3~4度治疗相关不良反应主要为高血压(19.4%)、手足皮肤反应(11.1%)、蛋白尿(5.6%)和贫血(5.6%)。 结论: 安罗替尼在晚期肾细胞癌的治疗中表现出良好的抗肿瘤活性,其血液学不良反应低,实验室检查指标异常、乏力、手足皮肤反应等与舒尼替尼和帕唑帕尼等药物相仿。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Song Y, Yihebali C, Yang L, et al. [Long term follow-up results of anlotinib in the treatment of advanced renal cell carcinoma]. Zhonghua Zhong Liu Za Zhi. 2020. PMID: 32988160. doi:10.3760/cma.j.cn112152-20200214-00089

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。